Important: New Login Process

We've updated our access and security system. The first time you log in, enter your work email, and we'll guide you through the process.

  • If your organization uses Single Sign-On (SSO), you will be redirected to your company's login portal.
  • If you log in with a username and password, you will be prompted to set a new password before accessing your account.

Go to the Login Page to get started.

We appreciate your cooperation during this transition. If you need assistance, please call +1 650-552-4224 or email support@biocentury.com.

BioCentury
ARTICLE | Clinical News

FDA accepts Sunovion's Aptiom sNDA for pediatric seizures

May 26, 2017 7:49 PM UTC

The Sunovion Pharmaceuticals Inc. unit of Sumitomo Dainippon Pharma Co. Ltd. (Tokyo:4506) said FDA accepted for review an sNDA for Aptiom eslicarbazepine acetate (Zebinix - EU) (BIA 2-093, SEP-0002093) as monotherapy or adjunctive therapy to treat partial-onset seizures in children ages ≥4. The voltage-gated sodium channel blocker is approved for the indications in adults...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article